Wedbush reissued their outperform rating on shares of Omeros (NASDAQ:OMER) in a report published on Tuesday morning. Wedbush currently has a $47.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Omeros’ Q4 2017 earnings at ($0.13) EPS, FY2017 earnings at ($0.95) EPS, Q1 2018 earnings at ($0.13) EPS, Q2 2018 earnings at ($0.09) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.24) EPS, FY2019 earnings at $0.74 EPS, FY2020 earnings at $1.81 EPS and FY2021 earnings at $3.13 EPS.

A number of other equities analysts have also recently weighed in on OMER. Maxim Group set a $24.00 price objective on Omeros and gave the company a buy rating in a report on Wednesday, August 2nd. Cantor Fitzgerald reissued a hold rating and set a $19.00 price objective (up from $15.00) on shares of Omeros in a report on Thursday, August 24th. Zacks Investment Research raised Omeros from a hold rating to a strong-buy rating and set a $22.00 price objective on the stock in a report on Thursday, October 19th. Cowen cut Omeros from an outperform rating to a market perform rating in a report on Thursday, November 2nd. Finally, HC Wainwright initiated coverage on Omeros in a report on Wednesday, November 8th. They set a buy rating and a $30.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Omeros currently has an average rating of Buy and an average target price of $34.14.

Shares of Omeros (NASDAQ OMER) opened at $20.74 on Tuesday. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros has a 12-month low of $8.71 and a 12-month high of $27.09.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to analysts’ expectations of $17.82 million. The business’s quarterly revenue was up 91.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.34) earnings per share. equities analysts predict that Omeros will post -0.96 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. First Interstate Bank purchased a new position in Omeros in the 3rd quarter worth approximately $108,000. Legal & General Group Plc increased its stake in Omeros by 7.8% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares during the period. Hanseatic Management Services Inc. increased its stake in Omeros by 10,919.6% in the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in Omeros in the 3rd quarter worth approximately $256,000. Finally, SG Americas Securities LLC increased its stake in Omeros by 138.9% in the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 7,067 shares during the period. 49.85% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Omeros (OMER) Given Outperform Rating at Wedbush” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/02/omeros-omer-given-outperform-rating-at-wedbush.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.